Table 2. Primary and Secondary Outcomes.
| Outcome | Patients, No./total No. (%) | Unadjusted analysis | Adjusted analysisa | |||||
|---|---|---|---|---|---|---|---|---|
| Chlorthalidone | Hydrochlorothiazide | HR (95% CI)b | Log-rank P value | Interaction P valuec | HR (95% CI)b | Log-rank P value | Interaction P valuec | |
| Composite primary outcome | ||||||||
| With MI or stroke history | 105/733 (14.3) | 140/722 (19.4) | 0.73 (0.57-0.94) | .01 | .002 | 0.74 (0.58-0.96) | .02 | .004 |
| Without MI or stroke history | 597/6023 (9.9) | 535/6045 (8.9) | 1.12 (1.00-1.26) | .054 | 1.12 (1.00-1.26) | .054 | ||
| Acute heart failure | ||||||||
| With MI or stroke history | 34/733 (4.6) | 52/722 (7.2) | 0.64 (0.41-0.98) | .04 | .01 | 0.64 (0.42-1.00) | .054 | .01 |
| Without MI or stroke history | 208/6023 (3.5) | 180/6045 (3.0) | 1.16 (0.95-1.42) | .15 | 1.17 (0.96-1.43) | .12 | ||
| MI | ||||||||
| With MI or stroke history | 24/733 (3.3) | 34/722 (4.7) | 0.70 (0.42-1.18) | .18 | .12 | 0.69 (0.40-1.16) | .16 | .10 |
| Without MI or stroke history | 118/6023 (2.0) | 106/6045 (1.8) | 1.11 (0.86-1.45) | .42 | 1.13 (0.87-1.47) | .38 | ||
| Stroke | ||||||||
| With MI or stroke history | 19/733 (2.6) | 16/722 (2.2) | 1.19 (0.62-2.32) | .60 | .56 | 1.15 (0.59-2.24) | .68 | .67 |
| Without MI or stroke history | 64/6023 (1.1) | 67/6045 (1.1) | 0.96 (0.68-1.35) | .79 | 0.98 (0.69-1.38) | .90 | ||
| Unstable angina requiring revascularization | ||||||||
| With MI or stroke history | 4/733 (0.5) | 3/722 (0.4) | 1.34 (0.30-5.97) | .70 | .83 | 1.48 (0.33-6.56) | .61 | .91 |
| Without MI or stroke history | 16/6023 (0.3) | 10/6045 (0.2) | 1.60 (0.73-3.53) | .24 | 1.63 (0.74-3.60) | .23 | ||
| Noncancer death | ||||||||
| With MI or stroke history | 55/733 (7.5) | 76/722 (10.5) | 0.72 (0.51-1.03) | .07 | .04 | 0.75 (0.53-1.07) | .11 | .06 |
| Without MI or stroke history | 304/6023 (5.0) | 278/6045 (4.6) | 1.09 (0.93-1.29) | .28 | 1.09 (0.93-1.29) | .29 | ||
Abbreviations: HR, hazard ratio; MI, myocardial infarction.
a
Adjusted for age, male sex, Black race, body mass index, history of diabetes, history of heart failure, smoking status, rurality of residence, and baseline use of sodium-glucose cotransport protein 2 inhibitor and mineralocorticoid receptor antagonist. There were 88 participants with missing body mass index values at baseline.
b
Hazard ratios were estimated using a Cox proportional hazards regression model for the primary outcome and a Fine-Gray model for secondary outcomes to account for competing risk with all-cause mortality.
c
Interaction between study treatment and history of MI or stroke.